Skip to content

Abliva

Delivering mitochondrial health

  • English
    • English
    • Svenska
  • Abliva
    • This is Abliva
      • Strategy
      • Orphan Drugs
    • Board
    • Team
    • Partners
    • Relevant publications
  • Mitochondrial Diseases
    • Primary mitochondrial diseases
      • MELAS-MIDD and KSS-CPEO
      • Leigh Syndrome
      • LHON
    • Patients
    • Expanded access policy
  • Research & Development
    • Portfolio
      • KL1333
      • NV354
      • Early programs
    • Clinical trials
      • The FALCON Study
    • Partnering
      • BD Contact
  • Investors
    • Financial reports
      • Annual reports
      • Interim reports
      • Other financial information
    • Financial Calendar
    • Share and owner information
    • Equity research
    • Corporate governance
      • General meeting
      • General meetings archive
    • IR contact
  • News
    • Press releases
    • Newsletters
    • Events and Presentations
      • World Mitochondrial Disease Week 2022
      • World Mitochondrial Disease Week 2021
    • Company Calendar
    • News subscription
    • Press photos
    • Media contact
    • Privacy policy
  • Contact

Press releases

  • All
  • 2023
  • 2022
  • 2021
  • 2020
  • 2019
  • 2018
  • 2017
  • 2016
  • 2015
  • 2014
  • 2013
  • 2012
  • 2011
  • 2010
All MARRegulatory
19 November, 2015
Regulatory

NeuroVive reports favourable safety evaluation in Phase II acute kidney injury study

Lund, Sweden, 19 November 2015 - NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that the independent safety committee has endorsed the continuation of the on-going P ...
Continue reading
18 November, 2015
Regulatory

NeuroVive: Interim Report 1 Jan. 2015 to 30 Sep. 2015

Focus forward on R&D
Continue reading
2 November, 2015
Regulatory

NeuroVive Presents Findings Targeting Complex I Deficiency at World Mitochondria Congress

Lund, Sweden, 2 November 2015 - NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces the presentation of preclinical data from its Complex I deficiency discovery program a ...
Continue reading
28 October, 2015
Regulatory

NeuroVive Aims to Find Path Forward in Antiviral Development Following Discontinuation of OCB-030 Preclinical Program by Arbutus

Lund, Sweden, 28 October 2015- NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that they will seek to find a suitable path forward to continue the development of the ...
Continue reading
23 October, 2015
Regulatory

NeuroVive Strengthens Clinical Development Team With Appointment of Dr. Magnus Hansson as Chief Medical Officer

Lund, Sweden, 23 October 2015 - NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces that Dr. Magnus Hansson will be appointed as Chief Medical Officer, effective as of 1 ...
Continue reading
16 October, 2015
Regulatory

Annual General Meeting 2016 and Nomination Committee

The Annual General Meeting of NeuroVive Pharmaceutical AB (publ) will be held on 28 April 2016 at 4 p.m. at Medicon Village, Scheelevägen 2, in Lund, Sweden.
Continue reading
1 September, 2015
Regulatory

NeuroVive announces departure of CEO and appointment of Jan Nilsson as interim CEO

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, announces a change in leadership of the company. Effective today, Mikael Brönnegård will no longer serve as Chief Executive Off ...
Continue reading
31 August, 2015
Regulatory

NeuroVive refocuses CicloMulsion development – discontinues acute myocardial infarction indication

CicloMulsion® development to continue in acute kidney injury and increased focus on development of other drug candidates. Shareholder information meeting to be held on 10th September 2015 in Lund, Swe ...
Continue reading
19 August, 2015
Regulatory

NeuroVive: Interim Report 1 Jan. 2015 to 31 Jun. 2015

Negative top-line result of phase III study and continued progress in other clinical projects
Continue reading
26 June, 2015
Regulatory

NeuroVive share upgraded on OTC market in US

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, has announced that the company's share has been upgraded from trading on the OTC Grey Market to OTC Pink in the US. The upgrade ...
Continue reading
1 June, 2015
Regulatory

NeuroVive reports topline results of phase III CIRCUS study in acute myocardial infarction

NeuroVive Pharmaceutical AB (publ), the mitochondrial medicine company, reports that the phase III CIRCUS study of CicloMulsion® in patients with a specific type of heart attack known as ST-segment el ...
Continue reading
29 May, 2015
Regulatory

NeuroVive Pharmaceutical AB (publ) – amendment number of shares and votes

Pursuant to chapter 4, § 9 of the Swedish Financial Instruments Trading Act (1991:980), the company is hereby reporting that as a result of new share issue conducted by NeuroVive Pharmaceutical AB (pu ...
Continue reading

Posts navigation

Older posts

Popular shortcuts

Research & Development
Investors
Primary mitochondrial diseases
Interim reports

Receive updates straight to your inbox

Choose the categories that you are interested in, and check preferred language.

  1. Startpage

This is Abliva

  • Strategy
  • Board
  • Team
  • Partners and advisers
  • Relevant publications

Research & Development

  • Research & Development
  • KL1333
  • NV354
  • Early programs
  • Partnering
  • BD Contact

Investors

  • Investors
  • Annual reports
  • Interim reports
  • Other financial information
  • Financial Calendar
  • Share and owner information
  • Equity research
  • Corporate governance
  • General meeting
  • General meetings archive
  • IR contact

News

  • Press releases
  • Newsletters
  • Events and Presentations
  • Capital Markets Day 2020
  • Mitochondria Day 2020
  • News subscription
  • Press photos
  • Media contact
  • Privacy policy

Contact

Abliva AB (publ)
Medicon Village
223 81 Lund, Sweden

Phone
+46 (0)46-275 62 20

Generel questions
info@abliva.com

© Copyright 2020 – Abliva AB. All rights reserved. | We use cookies to improve our services | Cookie policy | Privacy policy

Cookies
We serve cookies. If you think that's ok, just click "Accept all". You can also choose what kind of cookies you want by clicking "Settings". Read our cookie policy
Settings Accept all
Cookies
Choose what kind of cookies to accept. Your choice will be saved for one year. Read our cookie policy
  • Necessary
    These cookies are not optional. They are needed for the website to function.
  • Statistics
    In order for us to improve the website's functionality and structure, based on how the website is used.
  • Experience
    In order for our website to perform as well as possible during your visit. If you refuse these cookies, some functionality will disappear from the website.
  • Marketing
    By sharing your interests and behavior as you visit our site, you increase the chance of seeing personalized content and offers.
Save Accept all